Alzheimer's Disease Market Research Reports & Industry Analysis
A gradual loss of neurons later in adulthood does not result in significant alteration in brain function during the usual life span. However, the older one gets, the greater the neurologic impairment. Excessive neuronal degeneration in adulthood is called Alzheimer’s disease or senile dementia and is distinguished from the normal changes in aging. Alzheimer’s disease is a progressive disease which results in death of the brain cells causing memory lapses, behavioral issues, and disruption of thinking processes. The disease is considered fatal. Age and generic inheritance are the two key risk factors for developing Alzheimer’s disease. These are also risk factors that are not preventable. However, other preventable risk factors have been linked to the development of AD, including environment, diet, and overall general health. A combination of risk factors is often responsible for the disease.
Alzheimer’s disease is estimated to affect up to 6% of the population over 65. Life expectancy has been increasing around the world due to advances in healthcare, medical research, sanitation, and nutrition. This provides a setting for a higher number of Alzheimer’s disease patients in the future as the population continues to add years to their life.
Alzheimer's Disease Industry Research & Market Reports
-
Alzheimer's Disease Diagnostics & Therapeutics Market by Product (Diagnostics, Therapeutics), Disease Stage (Early, Moderate, Severe), End-User - Global Forecast 2024-2030
... 2023 and expected to reach USD 7.26 billion in 2024, at a CAGR 8.00% to reach USD 11.57 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's Disease ... Read More
-
Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer’s Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Global Forecast 2024-2030
... expected to reach USD 10.24 billion in 2024, at a CAGR 14.05% to reach USD 22.56 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Neurological Biomarkers Market. It ... Read More
-
Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Global Forecast 2024-2030
... billion in 2023 and expected to reach USD 10.78 billion in 2024, at a CAGR 10.39% to reach USD 19.58 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the ... Read More
-
Central Nervous System Biomarkers Market by Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease Indication (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease), Application, End-User - Global Forecast 2024-2030
... estimated at USD 4.37 billion in 2023 and expected to reach USD 4.81 billion in 2024, at a CAGR 10.39% to reach USD 8.73 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is ... Read More
-
Neurology Endoscopy Devices Market by Product (Accessories, Endoscopes, Operative Devices), Indication (Alzheimer’s Disorders, Brain Cancer, Brain Tumor), Usability, End User, Application - Global Forecast 2024-2030
... 5.19 billion in 2023 and expected to reach USD 5.56 billion in 2024, at a CAGR 7.22% to reach USD 8.46 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating ... Read More
-
South & Central America Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product (Single Channel Deep Brain Stimulator, Dual Channel Deep Brain Stimulator, and Software and Accessories), Application (Parkinson\'s Disease, Tremor, Dystonia, Epilepsy, Alzheimer\'s Disease, and Others), and End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Others)
... Dystonia, Epilepsy, Alzheimer\'s Disease, and Others), and End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Others) The South & Central America deep brain simulation market is expected to grow from US$ 27.53 million in ... Read More
-
Middle East & Africa Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product (Single Channel Deep Brain Stimulator, Dual Channel Deep Brain Stimulator, and Software and Accessories), Application (Parkinson\'s Disease, Tremor, Dystonia, Epilepsy, Alzheimer\'s Disease, and Others), and End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Others)
... Dystonia, Epilepsy, Alzheimer\'s Disease, and Others), and End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Others) The Middle East & Africa deep brain simulation market is expected to grow from US$ 25.64 million in ... Read More
-
Brain Biomarkers Market by Product (Biomarker Analyzers, Biomarker Test Kits), Indication (Alzheimer's Disease, Huntington's Disease, MND & ALS), End-Users, Application - Global Forecast 2024-2030
... in 2023 and expected to reach USD 10.54 billion in 2024, at a CAGR 17.90% to reach USD 28.33 billion by 2030. Global Brain Biomarkers Market FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal ... Read More
-
Alzheimer's Disease Drugs Market by Drug Class (Cholinergic, Combined Drug, Memantine), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030
... in 2023 and expected to reach USD 4.74 billion in 2024, at a CAGR 10.10% to reach USD 8.45 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's ... Read More
-
Neuroprotection Market by Product (Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists), Treatment (Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury), Application - Global Forecast 2024-2030
... 2023 and expected to reach USD 16.20 billion in 2024, at a CAGR 9.86% to reach USD 28.52 billion by 2030. FPNV Positioning Matrix The FPNV Positioning Matrix is pivotal in evaluating the Neuroprotection Market. ... Read More
-
Alzheimer's Drugs Global Market Report 2024
... AbbVie Inc.; Daiichi Sankyo Company Limited; F Hoffmann-La Roche AG; Merck & Co Inc.; Novartis AG Alzheimer's Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the ... Read More
-
Dementia Associated with Alzheimer's Disease Market (Drug Class: Cholinergic/Cholinesterase Inhibitors, Memantine, Combined Drugs, Others; Distribution Channel: Hospital Pharmacies, Retail, Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031
... Alzheimer's Disease Market – Scope of Report TMR’s report on the global dementia associated with Alzheimer’s disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of ... Read More
-
Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2024 - 2030
... global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased ... Read More
-
Alzheimer Disease Drugs Companies in China
... expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in ... Read More
-
Alzheimer Disease Drugs Markets in China
... Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's ... Read More
-
Alzheimer Disease Drugs Industry Forecasts - China Focus
... of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the ... Read More
-
Global Alzheimer's Disease Therapeutics Market 2024-2028
... alzheimer's disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current ... Read More
-
Neuroregeneration Therapy Market, By Type of Neuroregeneration Therapy (Stem Cell Therapy, Gene Therapy, Pharmacological Therapy, Neurostimulation Therapy, Others), By Indication (Spinal Cord Injury, Stroke, Traumatic Brain Injury, Parkinson\'s Disease, Alzheimer\'s Disease, Multiple Sclerosis, Peripheral Nerve Injury, Others), By Mode of Administration (Oral, Injectable, Implantable, Others), By Age Group (Pediatric, Adult, Geriatric), By End User (Hospitals, Specialty Clinics, Research Institutes, Rehabilitation Centers, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
... Injury, Others), By Mode of Administration (Oral, Injectable, Implantable, Others), By Age Group (Pediatric, Adult, Geriatric), By End User (Hospitals, Specialty Clinics, Research Institutes, Rehabilitation Centers, Others), By Geography (North America, Latin America, Europe, Middle ... Read More
-
Neurosurgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
... reach US$ 21.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.5% during 2023-2028. Neurosurgery devices refer to various tools and instruments that are used for conducting surgeries and treating various pathologies in the ... Read More
-
Glycomic Therapeutics Global Market Report 2023 Including: 1) By Class: Isolated; Synthetic 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher’s Disease; Mps-1 And IV; Cancer; Alzheimer’s Disease; Influenza Type A And B Covering: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
... Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons4) ... Read More
-
Europe Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
... and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 ... Read More
-
Asia Pacific Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
... COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, ... Read More
-
North America Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
... COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, ... Read More
-
Middle East & Africa Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)
... Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above ... Read More
-
Alzheimer’s Disease Market: Distribution by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030
... characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in ... Read More
Research Assistance
